Calamos Advisors LLC Has $51.24 Million Stock Holdings in Medtronic PLC $MDT

Calamos Advisors LLC increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 27.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 538,018 shares of the medical technology company’s stock after purchasing an additional 117,358 shares during the quarter. Calamos Advisors LLC’s holdings in Medtronic were worth $51,241,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in MDT. Wynn Capital LLC raised its holdings in shares of Medtronic by 2.4% during the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after acquiring an additional 110 shares during the period. Cape Investment Advisory Inc. raised its stake in shares of Medtronic by 3.2% in the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after purchasing an additional 113 shares during the period. Gilbert & Cook Inc. lifted its holdings in shares of Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after purchasing an additional 114 shares in the last quarter. Red Spruce Capital LLC boosted its position in shares of Medtronic by 0.5% during the second quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after buying an additional 118 shares during the period. Finally, Florida Financial Advisors LLC grew its holdings in shares of Medtronic by 4.8% during the second quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after buying an additional 122 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $96.68 on Wednesday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm’s fifty day moving average price is $97.56 and its two-hundred day moving average price is $93.92. Medtronic PLC has a 1 year low of $79.38 and a 1 year high of $106.33. The firm has a market capitalization of $123.94 billion, a P/E ratio of 26.06, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Analyst Upgrades and Downgrades

Several research firms have commented on MDT. Sanford C. Bernstein set a $111.00 target price on Medtronic in a research note on Wednesday, November 19th. Truist Financial lowered their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday. Wells Fargo & Company raised their target price on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Finally, Royal Bank Of Canada lifted their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).